Spots Global Cancer Trial Database for hct
Every month we try and update this database with for hct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection | NCT04017962 | CMV CMV Infection Hematopoietic C... | Letermovir Pill blood draw | 12 Years - | Memorial Sloan Kettering Cancer Center | |
| Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | NCT02851056 | Multiple Myelom... | Survivin Vaccin... Autologous Hema... Prevnar 13 Granulocyte-col... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | NCT02743351 | Hematologic Mal... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Acute Graft-ver... | ProTmune Control Arm | 18 Years - | Fate Therapeutics | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| A Long-term Follow-up Study of Patients Who Received VOR33 | NCT05309733 | Leukemia, Myelo... | VOR33 | - | Vor Biopharma | |
| Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant | NCT05709912 | Bone Marrow Tra... Hematologic Mal... | CARE Applicatio... Usual Care | 18 Years - | Massachusetts General Hospital | |
| A Long-term Follow-up Study of Patients Who Received VOR33 | NCT05309733 | Leukemia, Myelo... | VOR33 | - | Vor Biopharma | |
| A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection | NCT04017962 | CMV CMV Infection Hematopoietic C... | Letermovir Pill blood draw | 12 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals | |
| Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies | NCT04710212 | Hematologic Mal... Leukemia, Acute Neutropenia Bloodstream Inf... | No intervention... | 18 Years - | Duke University | |
| Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation | NCT03276481 | Multiple Myelom... | Oral microbiota... Comprehensive c... Measurement of ... Surveys assessi... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV | NCT05470491 | HIV Hematologic Mal... | RIC GVHD prophylaxi... allo HCT Plerixafor Maraviroc | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Intervention for Fatigue in HCT Recipients | NCT05715047 | Hematologic Can... Hematologic Mal... | CBT for Fatigue Usual Care | 18 Years - | Massachusetts General Hospital | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders | NCT06126341 | Multiple Myelom... | Lecture on the ... Hospital Anxiet... Duke-UNC Functi... Distress Thermo... FACT-BMT Psychosocial As... | 18 Years - 80 Years | Memorial Sloan Kettering Cancer Center | |
| A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders | NCT06126341 | Multiple Myelom... | Lecture on the ... Hospital Anxiet... Duke-UNC Functi... Distress Thermo... FACT-BMT Psychosocial As... | 18 Years - 80 Years | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Vera | NCT06290765 | Polycythemia Ve... Myeloproliferat... | Ropeginterferon... Phlebotomy | 18 Years - 59 Years | PharmaEssentia | |
| Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation | NCT01596699 | Myeloid Maligna... Bone Marrow Fai... Transfusion-dep... Congenital Immu... Metabolic Disea... Severe Immune D... | Alemtuzumab Busulfan Fludarabine Clofarabine | 3 Months - 30 Years | University of California, San Francisco | |
| Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation | NCT01809847 | Chronic Lymphat... | Ofatumumab | 56 Years - | Technische Universität Dresden | |
| Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation | NCT03276481 | Multiple Myelom... | Oral microbiota... Comprehensive c... Measurement of ... Surveys assessi... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | NCT04849910 | Leukemia, Myelo... Myelodysplastic... | VOR33 Mylotarg | 18 Years - 70 Years | Vor Biopharma | |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | NCT05735717 | Hematologic Mal... Acute Leukemia Remission Acute Myeloid L... Acute Lymphobla... AML TP53 Intrachromosoma... Cytogenetic Abn... CNS Leukemia Minimal Residua... Myelodysplasia Juvenile Myelom... Somatic Mutatio... PTPN11 Gene Mut... N-RAS Gene Ampl... Neurofibromatos... NF1 Mutation CBL Gene Mutati... Monosomy 7 Chromosome Abno... Fetal Hemoglobi... | Fludarabine Busulfan Melphalan Rituximab Levetiracetam | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | NCT04284228 | Acute Myeloid L... Myelodysplastic... | Infusion of NEX... | 18 Years - | NexImmune Inc. | |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | NCT05984199 | Leukemia, Myelo... | VCAR33 | 18 Years - | Vor Biopharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
